ANT-GROUP
3.11.2022 04:21:38 CET | Business Wire | Press release
Ant Group today officially launched its Alipay+ D-store™ at the Singapore FinTech Festival 2022. Alipay+ D-store™ is a business digitalization solution designed to support the service industry, especially brick-and-mortar businesses to digitalize their operations to boost efficiency and productivity.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221102006207/en/
(Photo: Business Wire)
An integrated one-stop solution which businesses can use to build digital stores across multiple digital platforms in a fast, scalable and cost-efficient way, Alipay+ D-store™ provides a suite of toolkits to digitalize merchants' payments, operations, services and marketing, unlocking new revenue opportunities and delivering better services to consumers.
Businesses could have digital stores on digital platforms in the form of mini programmes. Digital stores could also be developed as H5 pages and easily embedded in social media and online to reach consumers. Digital platforms currently partnering with Alipay+ D-store™ include Chope, Alipay, Touch 'n Go eWallet, AlipayHK, etc.
“We welcome more digital platforms to collaborate to accelerate the digitalization of the global service industry together,” Dr. Cherry Huang, Global Head of Alipay+ D-store™ said.
“Leveraging digital solutions is critical for the service industries to boost operational efficiency and adapt to the fast-changing market conditions. The Alipay+ D-store™ solution is developed with the goal to make it easier for brick-and-mortar businesses to go digital at scale, so that businesses can better serve and engage digital-savvy consumers by providing a seamless omni-channel experience,” she added.
Having identified the F&B industry a priority sector, Alipay+ D-store™ solution has been adopted by brands including fast food chain Burger King, Koufu, one of Singapore’s most established and largest operators and managers of food courts and coffee shops, and more than 2,000 local restaurants, cafes and eateries in Singapore, Malaysia, Hong Kong SAR, China and other markets.
At the Festival, Alipay+ D-store™ also unveiled its newest customer, Huggs Coffee, one of Singapore’s largest homegrown cafe chain brands specializing in coffee with over 20 outlets. Huggs will work with Alipay+ D-store™ to digitalize its outlets and operations efficacy, allowing customers to access seamless services through its digital store on Chope and other platforms in future.
Speaking in regard to the partnership, Lee Haoming, Managing Director of Huggs Coffee said: “Huggs is not only a business of F&B, to us, a good cup of coffee is a tool to create social connections. That is why creating a unique and elevated experience beyond the coffee itself is important to Huggs, and we believe digitalization plays an important role in enhancing the experience.”
“We are very excited to partner with Alipay+ D-store™ to transform the Huggs experience! It creates a more efficient operation flow to brew more smiles while reducing time to queue and pay, henceforth allowing our valued customers to spend more quality time on building connections with each other when visiting Huggs.”
To learn more about Alipay+ D-store™ at the Singapore FinTech Festival 2022, visit the Ant Group booth #2E01, or attend the product showcase “It’s A PLUS: How Alipay+ & Partners Build Digital Resilience For Businesses” scheduled at 11:20 a.m., 3 November in Hall 3.
About Ant Group
Ant Group aims to build the infrastructure and platforms to support the digital transformation of the service industry. Through continuous innovation, it strives to provide all consumers and small and micro businesses equal access to digital, financial, and other daily life services that are convenient, sustainable, and inclusive.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221102006207/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 16:44:00 CET | Press release
One SKU. Every market. Connectivity decided at the end of production. Live at electronica 2026. Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the pr
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom